Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats

Q2 Neuroscience

Current Protocols in Neuroscience Pub Date : 2019-05-03 DOI:10.1002/cpns.68

Fausto Pierdoná Guzen, José Rodolfo Lopes de Paiva Cavalcanti, Diogo Manuel Lopes de Paiva Cavalcanti, Luma Gabrielle Praxedes de Sales, Monalisa Stefany Martins da Silva, Aline Naiara Azevedo da Silva, Francisco Irochima Pinheiro, Dayane Pessoa de Araújo

{"title":"Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats","authors":"Fausto Pierdoná Guzen, José Rodolfo Lopes de Paiva Cavalcanti, Diogo Manuel Lopes de Paiva Cavalcanti, Luma Gabrielle Praxedes de Sales, Monalisa Stefany Martins da Silva, Aline Naiara Azevedo da Silva, Francisco Irochima Pinheiro, Dayane Pessoa de Araújo","doi":"10.1002/cpns.68","DOIUrl":null,"url":null,"abstract":"<p>Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia. This drug acts by blocking dopamine D2 receptors, reducing psychotic symptoms. Notwithstanding its benefits, haloperidol also produces undesirable impacts, in particular extrapyramidal effects such as tardive dyskinesia (TD), which limit the use of this and related drugs. TD is characterized by repetitive involuntary movements occurring after chronic exposure therapy with haloperidol. Symptoms most commonly manifest in the orofacial area and include involuntary movements, tongue protrusion, pouting lips, chewing in the absence of any object to chew, and facial grimacing. The most serious aspect of TD is that it may persist for months or years after drug withdrawal and is irreversible in some patients. This unit, aimed at facilitating the study of TD, describes methods to induce TD in rats using haloperidol, as well as procedures for evaluating the animals's TD-related symptoms. © 2019 by John Wiley & Sons, Inc.</p>","PeriodicalId":40016,"journal":{"name":"Current Protocols in Neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpns.68","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpns.68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Neuroscience","Score":null,"Total":0}

引用次数: 8

Abstract

Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia. This drug acts by blocking dopamine D2 receptors, reducing psychotic symptoms. Notwithstanding its benefits, haloperidol also produces undesirable impacts, in particular extrapyramidal effects such as tardive dyskinesia (TD), which limit the use of this and related drugs. TD is characterized by repetitive involuntary movements occurring after chronic exposure therapy with haloperidol. Symptoms most commonly manifest in the orofacial area and include involuntary movements, tongue protrusion, pouting lips, chewing in the absence of any object to chew, and facial grimacing. The most serious aspect of TD is that it may persist for months or years after drug withdrawal and is irreversible in some patients. This unit, aimed at facilitating the study of TD, describes methods to induce TD in rats using haloperidol, as well as procedures for evaluating the animals's TD-related symptoms. © 2019 by John Wiley & Sons, Inc.

查看原文本刊更多论文

氟哌啶醇致大鼠临床前迟发性运动障碍模型

氟哌啶醇是第一代用于治疗精神病，特别是精神分裂症的抗精神病药物。这种药物通过阻断多巴胺D2受体，减轻精神病症状。尽管氟哌啶醇有好处，但它也会产生不良影响，特别是锥体外系效应，如迟发性运动障碍(TD)，这限制了氟哌啶醇和相关药物的使用。慢性氟哌啶醇暴露治疗后，TD的特点是反复出现不自主运动。症状最常见于口面部，包括不自主运动、舌头突出、撅嘴、无物咀嚼和面部鬼脸。TD最严重的方面是，它可能在停药后持续数月或数年，并且在一些患者中是不可逆转的。本单元旨在促进TD的研究，描述了使用氟哌啶醇诱导大鼠TD的方法，以及评估动物TD相关症状的程序。©2019 by John Wiley &儿子,Inc。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Protocols in Neuroscience Neuroscience-Neuroscience (all)

自引率

0.00%

发文量

期刊介绍： Current Protocols in Neuroscience is a one-stop resource for finding and adapting the best models and methods for all types of neuroscience experiments. Updated every three months in all formats, CPNS is constantly evolving to keep pace with the very latest discoveries and developments. A year of these quarterly updates is included in the initial CPNS purchase price.